Neutrophil-lymphocyte Ration Difference in Squamous Cell Carcinoma and Adenocarcinoma of Cervical Cancer

Rislefia Amadina Sinaga; Aditiyono Aditiyono; Andi Kurniadi

doi:10.24198/obgynia.v7i3.732

Neutrophil-lymphocyte Ration Difference in Squamous Cell Carcinoma and Adenocarcinoma of Cervical Cancer

Rislefia Amadina Sinaga, Aditiyono Aditiyono, Andi Kurniadi

Abstract

Introduction: Cervical cancer is the most commonly found malignancy in female reproductive system. There are two most found types of this cancer based on histopathologic finding, adenocarcinoma and squamous cell carcinoma (SCC). Each type has different outcome, especially in later stages. Neutrophil-lymphocyte ratio (NLR) is an indicator that can pinpoint the inflammation severity level, hence able to predict outcome and prognosis in malignancy, including cervical cancer.
Objective: This study aimed to determine the difference of NLR in both types of cervical cancer
Methods: This study used retrospective analytic observational with cross-sectional design. Data was sampled from Prof. dr. Margono Soekarjo General Regional Hospital medical record from patients diagnosed with cervical cancer of both types during January to December 2022. Mann-Whitney test was performed to determine the difference of NLR value between both types of cervical cancer.
Result: Between January and December 2022, 68 patients were diagnosed with cervical cancer. Of these, 37 (54.41%) had squamous cell carcinoma (SCC) and 31 (45.59%) had adenocarcinoma. The neutrophil-to-lymphocyte ratio (NLR) ranged from 1.55 to 25.99 in SCC patients, with a mean value of [insert mean value here]. For adenocarcinoma patients, the NLR ranged from 1.32 to 11.99.
Conclusion: Neutrophil-lymphocyte ratio can’t differentiate squamous cell carcinoma and adenocarcinoma of cervival cancer.

Perbedaan Rasio Neutrofil Limfosit pada Kanker Serviks Tipe Karsinoma Sel Skuamosa dan Tipe Adenokarsinoma

Abstrak
Pendahuluan: Kanker serviks merupakan keganasan yang paling banyak ditemukan pada sistem reproduksi wanita. Berdasarkan temuan histopatologi, terdapat dua jenis kanker serviks yang paling banyak ditemukan, yaitu adenokarsinoma dan karsinoma sel skuamosa (SCC). Setiap jenis memiliki hasil yang berbeda, terutama pada tahap selanjutnya. Rasio neutrofil-limfosit (NLR) merupakan salah satu indikator yang dapat digunakan untuk mengetahui tingkat keparahan inflamasi sehingga dapat memprediksi outcome dan prognosis pada suatu keganasan, termasuk kanker serviks.
Tujuan: Penelitian ini bertujuan untuk mengetahui perbedaan NLR pada kedua jenis kanker serviks
Metode: Penelitian ini menggunakan metode observasional analitik retrospektif dengan desain cross-sectional. Data diambil dari rekam medis RSUD Prof. dr. Margono Soekarjo mengenai pasien yang terdiagnosis kanker serviks kedua jenis tersebut selama bulan Januari hingga Desember 2022. Uji Mann-Whitney dilakukan untuk mengetahui perbedaan nilai NLR antara kedua jenis kanker serviks tersebut.
Hasil: Antara Januari dan Desember 2022, terdapat 68 pasien yang terdiagnosis kanker serviks. Dari jumlah tersebut, 37 (54,41%) menderita karsinoma sel skuamosa (SCC) dan 31 (45,59%) menderita adenokarsinoma. Rasio neutrofil terhadap limfosit (NLR) berkisar antara 1,55 hingga 25,99 pada pasien SCC, dengan nilai rata-rata [masukkan nilai rata-rata di sini]. Untuk pasien adenokarsinoma, NLR berkisar antara 1,32 hingga 11,99.
Kesimpulan: Rasio neutrofil-limfosit tidak dapat membedakan karsinoma sel skuamosa dan adenokarsinoma kanker serviks.

Kata kunci: Adenokarsinoma, Kanker Serviks, Rasio Neutrofil-Limfosit,

Keywords

Cervical cancer; NLR; SCC; Adenocarcinoma

Full Text:

PDF

References

Nasional KPK. Pedoman Nasional Pelayanan Kedokteran: Kanker Serviks. 2017.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.

Kementerian Kesehatan Republik Indonesia. InfoDATIN : Pusat Data dan Informasi Kementerian Kesehatan RI. 2018.

Hoffman BL, Schorge JO, Bradshaw KD, Halvorson LM, Schaffer JL, Corton MM. Cervical Cancer. In: William Gynecology. 3rd ed. New York: McGraw Hill; 2016. p. 657–75

Gien LT, Beauchemin MC, Thomas G. Adenocarcinoma: A unique cervical cancer. Gynecol Oncol. 2010;116(1):140–6.

Huang Z, Fu Z, Huang W, Huang K. Prognostic value of neutrophil-to-lymphocyte ratio in sepsis: A meta-analysis. Am J Emerg Med. 2019;38(3):641–7.

Yilmaz H, Yalcin KS, Namuslu M, Celik HT, Sozen M, Inan O, et al. Neutrophil-lymphocyte ratio (NLR) could be better predictor than C-reactive protein (CRP) for liver fibrosis in non-alcoholic steatohepatitis(NASH). Ann Clin Lab Sci. 2015;45(3):278–86.

Ma A, Cheng J, Yang J, Dong M, Liao X, Kang Y. Neutrophil-to-lymphocyte ratio as a predictive biomarker for moderate-severe ARDS in severe COVID-19 patients. Crit Care. 2020;24(288):24–7.

Adamstein NH, MacFadyen JG, Rose LM, Glynn RJ, Dey AK, Libby P, et al. The neutrophil-lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials. Eur Heart J. 2021;42(9):896–903.

Prabawa IPY, Bhargah A, Liwang F, Tandio DA, Tandio AL, Lestari AAW, et al. Pretreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as a predictive value of hematological markers in cervical cancer. Asian Pacific J Cancer Prev. 2019;20(3):863–8.

Ittiamornlert P, Ruengkhachorn I. Neutrophil-lymphocyte ratio as a predictor of oncologic outcomes in stage IVB, persistent, or recurrent cervical cancer patients treated by chemotherapy. BMC Cancer. 2019;19(1):1–10.

Nakamura K, Nakayama K, Tatsumi N, Minamoto T, Ishibashi T, Ohnishi K, et al. Prognostic significance of pre‑treatment neutrophil‑to‑lymphocyte and platelet‑to‑lymphocyte ratios in non‑surgically treated uterine cervical carcinoma. Mol Clin Oncol. 2018;138–44.

Chun S, Shin K, Kim KH, Kim HY, Eo W, Lee JY, et al. The neutrophil-lymphocyte ratio predicts recurrence of cervical intraepithelial neoplasia. J Cancer. 2017;8(12):2205–11.

Ramakrishnan S, Partricia S, Mathan G. Overview of high-risk HPV’s 16 and 18 infected cervical cancer: Pathogenesis to prevention. Biomedicine and Pharmacotherapy. 2015;70(C):103–10.

Wang L, Jia J, Lin L, Guo J, Ye X, Zheng X, et al. Predictive value of hematological markers of systemic inflammation for managing cervical cancer [Internet]. Vol. 8, Oncotarget. 2017. Available from: www.impactjournals.com/oncotarget/

Jonska-Gmyrek J, Gmyrek L, Zolciak-Siwinska A, Kowalska M, Fuksiewicz M, Kotowicz B. Pretreatment neutrophil to lymphocyte and platelet to lymphocyte ratios as predictive factors for the survival of cervical adenocarcinoma patients. Cancer Manag Res. 2018;10:6029–38.

Han X, Liu S, Yang G, Hosseinifard H, Imani S, Yang L, et al. Prognostic value of systemic hemato-immunological indices in uterine cervical cancer: A systemic review, meta-analysis, and meta-regression of observational studies. Gynecol Oncol. 2021 Jan 1;160(1):351–60.

Huang H, Liu Q, Zhu L, Zhang Y, Lu X, Wu Y, et al. Prognostic Value of Preoperative Systemic Immune-Inflammation Index in Patients with Cervical Cancer. Sci Rep. 2019 Dec 1;9(1).

Zhang L, Mao Z, Lai Y, Wan T, Zhang K, Zhou B. A review of the research progress in T-lymphocyte immunity and cervical cancer. Vol. 9, Translational Cancer Research. AME Publishing Company; 2020. p. 2026–36.

Liu P, Ji M, Kong Y, Huo Z, Lv Q, Xie Q, et al. Comparison of survival outcomes between squamous cell carcinoma and adenocarcinoma/adenosquamous carcinoma of the cervix after radical radiotherapy and chemotherapy. BMC Cancer. 2022 Dec 1;22(1).

DOI: http://dx.doi.org/10.24198/obgynia.v7i3.732